NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
Clinical Trials
17 trialsNCT01288911 2024-12-06
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT04284761 2024-06-24
Biolen-PC
Alessa Therapeutics Inc.
Phase 1 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT01664923 2019-01-30
STRIVE
Pfizer
Phase 2 Completed
NCT00959335 2017-03-28
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
Sandoz
Phase 1 Completed
NCT00960310 2017-03-28
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
Sandoz
Phase 1 Completed
NCT00470834 2017-02-27
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
GlaxoSmithKline
Phase 4 Completed
NCT00846976 2015-01-21
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00884273 2013-11-13
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals
Phase 3 Completed
NCT00833248 2012-10-04
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00075192 2012-06-06
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
AstraZeneca
Phase 1/2 Completed
NCT00657904 2012-06-06
Bicalutamide (Casodexâ„¢) Versus Placebo in Patients With Early Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00233610 2011-01-27
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00672282 2009-05-27
SPCG6
AstraZeneca
Phase 3 Completed
NCT00841113 2009-02-11
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Speciality European Pharma Limited
Phase 3 Completed
NCT00590213 2008-01-25
COMART
AstraZeneca
Phase 4 Completed